Naptumomab estafenatox
From Self-sufficiency
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Template:Infobox drug/mab source |
| Target | 5T4 |
| Identifiers | |
| CAS Number | 676258-98-3 |
| ATC code | none |
| Chemical data | |
| Formula | C3255H5025N855O1050S18 |
| Molar mass | 73.5 kDa[[Script error: No such module "String".]] |
Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer like non-small cell lung carcinoma[1] and renal cell carcinoma[2].
File:Fab-superantigen-fusion protein.svg
Schematic image of naptumomab estafenatox.
VH, VL: variable (antigen binding) domains of antibody fragment
CH1, CL: constant domains of antibody fragment
SAg: superantigen SEA/E-120
VH, VL: variable (antigen binding) domains of antibody fragment
CH1, CL: constant domains of antibody fragment
SAg: superantigen SEA/E-120
Mechanism of action
Chemically, it is a fusion protein consisting of the antigen-binding fragment (Fab) of a monoclonal antibody with the superantigen staphylococcal enterotoxin E (SEA/E-120, "estafenatox").[3] The Fab binds to 5T4, an antigen expressed by various tumor cells, and the superantigen induces an immune response by activating T lymphocytes.
See also
- Nacolomab tafenatox, a drug with a similar chemical structure and mechanism
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 40x30px | This monoclonal antibody-related article is a stub. You can help ssf by expanding it. |
- ↑ Borghaei, H; Alpaugh, K; Hedlund, G; Forsberg, G; Langer, C; Rogatko, A; Hawkins, R; Dueland, S; Lassen, U (2009). "Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27 (25): 4116–23. doi:10.1200/JCO.2008.20.2515. PMC 2734423 Freely accessible. PMID 19636016.
- ↑ ClinicalTrials.gov
- ↑ WHO Drug Information
Categories:
- Pages with script errors
- Drugs that are a monoclonal antibody
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Pages with broken file links
- 2Fix
- Cancer treatments
- Monoclonal antibody stubs
